New drug cocktail aims to outsmart aggressive blood cancer
NCT ID NCT07680933
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy, with or without a stem cell transplant, can improve outcomes for people newly diagnosed with an aggressive type of non-Hodgkin lymphoma called DLBCL. The study enrolls 30 adults aged 18-80 with CD20-positive DLBCL and an IPI score of 2-5. The main goal is to see how many participants remain cancer-free one year after starting treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib combined with standard immunochemotherapy (Pola-R-CHP or R-CHOP) with or without autologous hematopoietic stem cell transplantation
What this could lead to
If successful, this combination could offer a more effective first-line treatment for aggressive DLBCL, potentially improving long-term disease control and reducing relapse risk.
What could go wrong
This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply broadly. Adding orelabrutinib to chemotherapy increases the risk of side effects like infections, bleeding, and organ toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Orelabrutinib for MCD Subtype DLBCL Trial NCT07677813
- Quality of Life After CAR-T for Lymphoma (NCT06026644)
- SCTB35 for Relapsed/Refractory DLBCL Trial (NCT07570823)
- CT1182 for Relapsed/Refractory NHL - NCT07548697
- CL-Pola-R-CHP for Double/Triple-Hit Lymphoma NCT07552324
- New Lymphoma Treatment Study (NCT07511114)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••